EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Blocking EREG/GPX4 Sensitizes Head and Neck Cancer to Cetuximab through Ferroptosis Induction

Aude Jehl iD, Ombline Conrad iD, Mickaël Burgy iD, Sophie Foppolo iD, Romain Vauchelles, Carole Ronzani, Nelly Etienne-Selloum iD, Marie-Pierre Chenard, Aurélien Danic, Thomas Dourlhes, Claire Thibault, Philippe Schultz und 2 weitere

Cells · 24.02.2023 · 12 (5) · 733

DOI: 10.3390/cells12050733 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 24.02.2023. Verfasst von Aude Jehl und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Bioimaging and Pathology, University of Strasbourg, UMR7021 CNRS, 67401 Illkirch, France. Hauptthemen laut MEDLINE: Ferroptosis, Head and Neck Neoplasms. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Interdisciplinary Thematic Institute program of the University of Strasbourg, Ligue Contre le Cancer, Conférence de coordination interrégionale du Grand Est programme-inter region, URPS Chirurgiens Dentistes Grand Est.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

(1)

Background

Epiregulin (EREG) is a ligand of EGFR and ErB4 involved in the development and the progression of various cancers including head and neck squamous cell carcinoma (HNSCC). Its overexpression in HNSCC is correlated with short overall survival and progression-free survival but predictive of tumors responding to anti-EGFR therapies. Besides tumor cells, macrophages and cancer-associated fibroblasts shed EREG in the tumor microenvironment to support tumor progression and to promote therapy resistance. Although EREG seems to be an interesting therapeutic target, no study has been conducted so far on the consequences of EREG invalidation regarding the behavior and response of HNSCC to anti-EGFR therapies and, more specifically, to cetuximab (CTX); (2)

Methods

EREG was silenced in various HNSCC cell lines. The resulting phenotype (growth, clonogenic survival, apoptosis, metabolism, ferroptosis) was assessed in the absence or presence of CTX. The data were confirmed in patient-derived tumoroids; (3)

Results

Here, we show that EREG invalidation sensitizes cells to CTX. This is illustrated by the reduction in cell survival, the alteration of cell metabolism associated with mitochondrial dysfunction and the initiation of ferroptosis characterized by lipid peroxidation, iron accumulation and the loss of GPX4. Combining ferroptosis inducers (RSL3 and metformin) with CTX drastically reduces the survival of HNSCC cells but also HNSCC patient-derived tumoroids; (4)

Conclusions

The loss of EREG might be considered in clinical settings as a predictive biomarker for patients that might undergo ferroptosis in response to CTX and that might benefit the most from the combination of ferroptosis inducers and CTX.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisHead and Neck NeoplasmsHumansCetuximabEpiregulinIntercellular Signaling Peptides and ProteinsSquamous Cell Carcinoma of Head and NeckTumor MicroenvironmentPhospholipid Hydroperoxide Glutathione Peroxidase

Stichwörter der Autor:innen

EREGautophagybiomarkersferroptosishead and neck cancersmetabolismtumoroid

Substanzen

CetuximabEpiregulinIntercellular Signaling Peptides and ProteinsEREG protein, humanGPX4 protein, humanPhospholipid Hydroperoxide Glutathione Peroxidase

Autor:innen und Institutionen

  • Laboratory of Bioimaging and Pathology, University of Strasbourg, UMR7021 CNRS, 67401 Illkirch, France.
  • Department of Medical Oncology, Institute of Cancerology Strasbourg Europe, 67200 Strasbourg, France.
  • Laboratory of Design and Application of Bioactive Molecules, University of Strasbourg, UMR7199, CNRS, 67400 Illkirch, France.
  • Department of Pharmacy, Institute of Cancerology Strasbourg Europe, 67200 Strasbourg, France.
  • Department of Pathology, Strasbourg University Hospital, 67200 Strasbourg, France.
  • Department of Otolaryngology and Cervico-Facial Surgery, Strasbourg University Hospital, 67200 Strasbourg, France.

ORCID-Profile: Aude Jehl, Ombline Conrad, Mickaël Burgy, Sophie Foppolo, Nelly Etienne-Selloum, Monique Dontenwill, Sophie Martin

Förderung

  • Interdisciplinary Thematic Institute program of the University of Strasbourg
  • Ligue Contre le Cancer, Conférence de coordination interrégionale du Grand Est programme-inter region
  • URPS Chirurgiens Dentistes Grand Est

Zitieren

APA

Jehl, A., Conrad, O., Burgy, M., Foppolo, S., Vauchelles, R., Ronzani, C., Etienne-Selloum, N., Chenard, M. P., Danic, A., Dourlhes, T., Thibault, C., Schultz, P., Dontenwill, M., & Martin, S. (2023). Blocking EREG/GPX4 Sensitizes Head and Neck Cancer to Cetuximab through Ferroptosis Induction. Cells, 12(5), 733. https://doi.org/10.3390/cells12050733

Vancouver

Jehl A, Conrad O, Burgy M, Foppolo S, Vauchelles R, Ronzani C, et al. Blocking EREG/GPX4 Sensitizes Head and Neck Cancer to Cetuximab through Ferroptosis Induction. Cells. 2023;12(5):733. doi:10.3390/cells12050733

BibTeX
@article{Jehl2023,
  author = {Jehl, Aude and Conrad, Ombline and Burgy, Mickaël and Foppolo, Sophie and Vauchelles, Romain and Ronzani, Carole and Etienne-Selloum, Nelly and Chenard, Marie-Pierre and Danic, Aurélien and Dourlhes, Thomas and Thibault, Claire and Schultz, Philippe and Dontenwill, Monique and Martin, Sophie},
  title = {Blocking EREG/GPX4 Sensitizes Head and Neck Cancer to Cetuximab through Ferroptosis Induction},
  journal = {Cells},
  year = {2023},
  volume = {12},
  number = {5},
  pages = {733},
  doi = {10.3390/cells12050733}
}
Kostenlos starten →